CAR-T Cells in Canada; Perspective on How to Ensure We Get Our Value's Worth

Overview

Journal Curr Oncol

Publisher MDPI

Specialty Oncology

Date 2023 May 15

PMID 37185418

Authors

Pierre J A Villeneuve

Christopher Bredeson

Affiliations

Soon will be listed here.

Abstract

New therapies in a publicly funded healthcare system are first appraised by health technology assessment agencies that provide funding recommendations to the payers. Treatment with Chimeric Antigen Receptor-T cell (CAR-T) therapy is revolutionizing the management of patients with relapsed/refractory aggressive B-cell lymphoma by providing an effective alternative to the standard of care. Yet, the implementation of CAR-T treatment has a substantial impact on the healthcare system due to its high cost, complex manufacturing process, and requirement for highly specialized services and expertise. CAR-T Cells, as a "living drug", are fundamentally different from usual medications, and their approvals and funding recommendations pose unique challenges to the health technology agency. In this paper, we explore the specific challenges that face the health technology agencies in reviewing reimbursement recommendations for CAR-T therapy. We take a Canadian perspective and use CAR-T treatment of relapse/refractory aggressive B-cell lymphoma as an example.

Citing Articles

Chimeric Antigen Receptor T-Cell-Associated Cholangiopathy: First Reported Case of a Complication of Chimeric Antigen Receptor T-Cell Therapy.

Huang A, Kim H, Zhao B, Owen D, Jain A, Chahal D ACG Case Rep J. 2025; 12(1):e01597.

PMID: 39866330 PMC: 11759319. DOI: 10.14309/crj.0000000000001597.

Primary Refractory Discordant Diffuse Large B-Cell and Classical Hodgkin Lymphoma.

Bai Y, Bolger S, Khan S, Sangle N, Wang L, Cervi A J Hematol. 2024; 13(5):238-244.

PMID: 39493609 PMC: 11526587. DOI: 10.14740/jh1303.

Review of CAR T-Cell Therapy in Multiple Myeloma: A Canadian Perspective.

Shih S, Bhella S Curr Oncol. 2024; 31(7):3949-3967.

PMID: 39057164 PMC: 11276237. DOI: 10.3390/curroncol31070292.

References

Bishop M, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N . Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med. 2021; 386(7):629-639. DOI: 10.1056/NEJMoa2116596. View

Locke F, Neelapu S, Bartlett N, Siddiqi T, Chavez J, Hosing C . Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Mol Ther. 2017; 25(1):285-295. PMC: 5363293. DOI: 10.1016/j.ymthe.2016.10.020. View

Howell T, Matza L, Jun M, Garcia J, Powers A, Maloney D . Health State Utilities for Adverse Events Associated with Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma. Pharmacoecon Open. 2022; 6(3):367-376. PMC: 9043043. DOI: 10.1007/s41669-021-00316-0. View

Chakraborty R, Sidana S, Shah G, Scordo M, Hamilton B, Majhail N . Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities. Biol Blood Marrow Transplant. 2018; 25(5):e155-e162. PMC: 6511294. DOI: 10.1016/j.bbmt.2018.11.025. View

Hill J, Krantz E, Hay K, Dasgupta S, Stevens-Ayers T, Bender Ignacio R . Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy. Blood Adv. 2019; 3(22):3590-3601. PMC: 6880890. DOI: 10.1182/bloodadvances.2019000717. View

Jose A, Bavetta M, Martinelli E, Bronte F, Giunta E, Manu K . Hepatocellular Carcinoma: Current Therapeutic Algorithm for Localized and Advanced Disease. J Oncol. 2023; 2022:3817724. PMC: 9825221. DOI: 10.1155/2022/3817724. View

Jorgensen J, Hanna E, Kefalas P . Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries. J Mark Access Health Policy. 2020; 8(1):1715536. PMC: 7006635. DOI: 10.1080/20016689.2020.1715536. View

Elsawy M, Chavez J, Avivi I, Larouche J, Wannesson L, Cwynarski K . Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma. Blood. 2022; 140(21):2248-2260. PMC: 10653042. DOI: 10.1182/blood.2022015478. View

Stefanski H, Eaton A, Baggott C, Rossoff J, Verneris M, Prabhu S . Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium. Blood Adv. 2022; 7(4):541-548. PMC: 9979765. DOI: 10.1182/bloodadvances.2022007246. View

10.

Sidana S, Dueck A, Thanarajasingam G, Griffin J, Thompson C, Durani U . Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant. Transplant Cell Ther. 2022; 28(8):473-482. PMC: 9357185. DOI: 10.1016/j.jtct.2022.05.004. View

11.

Chong E, Ruella M, Schuster S . Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy. N Engl J Med. 2021; 384(7):673-674. DOI: 10.1056/NEJMc2030164. View

12.

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

13.

Crump M, Neelapu S, Farooq U, Van den Neste E, Kuruvilla J, Westin J . Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017; 130(16):1800-1808. PMC: 5649550. DOI: 10.1182/blood-2017-03-769620. View

14.

Roschewski M, Longo D, Wilson W . CAR T-Cell Therapy for Large B-Cell Lymphoma - Who, When, and How?. N Engl J Med. 2021; 386(7):692-696. PMC: 9295142. DOI: 10.1056/NEJMe2118899. View

15.

Kekre N, Hay K, Webb J, Mallick R, Balasundaram M, Sigrist M . CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies. Front Immunol. 2023; 13:1074740. PMC: 9806210. DOI: 10.3389/fimmu.2022.1074740. View

16.

Martinez-Cibrian N, Espanol-Rego M, Pascal M, Delgado J, Ortiz-Maldonado V . Practical aspects of chimeric antigen receptor T-cell administration: From commercial to point-of-care manufacturing. Front Immunol. 2022; 13:1005457. PMC: 9550897. DOI: 10.3389/fimmu.2022.1005457. View

17.

Ruark J, Mullane E, Cleary N, Cordeiro A, Bezerra E, Wu V . Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy. Biol Blood Marrow Transplant. 2019; 26(1):34-43. PMC: 6951812. DOI: 10.1016/j.bbmt.2019.09.037. View

18.

Stefanini B, Ielasi L, Chen R, Abbati C, Tonnini M, Tovoli F . TKIs in combination with immunotherapy for hepatocellular carcinoma. Expert Rev Anticancer Ther. 2023; 23(3):279-291. DOI: 10.1080/14737140.2023.2181162. View

19.

Grigor E, Fergusson D, Kekre N, Montroy J, Atkins H, Seftel M . Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis. Transfus Med Rev. 2019; 33(2):98-110. DOI: 10.1016/j.tmrv.2019.01.005. View

20.

Srikanthan A, Mai H, Penner N, Amir E, Laupacis A, Sabharwal M . Impact of the pan-Canadian Oncology Drug Review on provincial concordance with respect to cancer drug funding decisions and time to funding. Curr Oncol. 2017; 24(5):295-301. PMC: 5659150. DOI: 10.3747/co.24.3648. View